Non-Invasive methods to Determine Vulnerable Plaque Burden in Subjects

摘要

Methods, kits, and systems for determining vulnerable plaque burden in a subject. The methods involve measuring an amount of at least one biomarker in a blood sample from the subject, wherein the at least one biomarker is selected from the group consisting of vascular endothelial growth factor-A (VEGF), cardiac troponin I (cTnI), and matrix metalloproteinase-9 (MMP-9). The concentration of these biomarkers in a sample from the subject are used to determine vulnerable plaque burden in the subject.

主权项

1. A method for determining vulnerable plaque burden in a subject comprising:
measuring an amount of at least one biomarker in a blood, serum or plasma sample from the subject, wherein the at least one biomarker is selected from the group consisting of vascular endothelial growth factor-A (VEGF), cardiac troponin I (cTnI), and matrix metalloproteinase-9 (MMP-9); comparing the amount of the at least one biomarker in the biological sample from the subject to a threshold concentration representing the concentration of the at least one biomarker in a population of normal healthy control subjects, and determining vulnerable plaque burden in the subject when the concentration of at least one biomarker in the sample is greater than the threshold concentration.